• Explore /
  • Poster
  • / Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

Abstract Poster

Authors

Evan Yu

Evan Y. Yu

University of Washington, Seattle, WA

Evan Y. Yu , Anthony M. Joshua , Neal D. Shore , Gero Kramer , Haixia Hu , Christian Heinrich Poehlein , Charles Schloss , Johann S. De Bono

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02861573

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS250)

DOI

10.1200/JCO.2024.42.4_suppl.TPS250

Abstract #

TPS250

Poster Bd #

Q11

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Genitourinary Cancers Symposium

The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).

First Author: Guo Hongqian

First Author: Peter C.C. Fong

First Author: Evan Y. Yu

First Author: Shahneen Sandhu